Australian and European Patent Offices Grant the Company Four Patents Relating to Key Innovations in Implantable System Design, Signal Analysis, and Battery Recharge Safety
White Bear Lake, Minnesota--(Newsfile Corp. - May 20, 2026) - Envoy Medical® Inc. (NASDAQ: COCH), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of multiple patents across Australia and Europe, as well as the upcoming grant of an additional European patent, further expanding the Company's intellectual property portfolio and reinforcing its position in the cochlear implant industry.
"As we continue advancing fully implanted hearing technology, protecting the innovation behind these systems remains a key priority for Envoy Medical," said Brent Lucas, CEO, Envoy Medical. "These patents further strengthen our intellectual property portfolio across critical areas including implant architecture, signal processing, and rechargeable battery systems, while reinforcing our long-term position in the cochlear implant market."
The newly granted and pending patents cover technologies related to fully implanted cochlear implant platforms, removable earplug sensors, implanted battery systems, integrated signal analysis functionality, and rechargeable implant battery management.
The Australian Patent Office granted Australian Patent No. 2022227537 to Envoy Medical Corporation on July 3, 2025. Titled Combination Implant System with Removable Earplug Sensor and Implanted Battery, the patent relates to cochlear implant systems featuring (i) an implantable subsystem with a stimulator and rechargeable energy storage and (ii) a removable earplug that can receive electrical power from the implantable subsystem and that includes a sensor and a signal processor configured to generate stimulation signals and output the stimulation signals to the implantable subsystem.
The European Patent Office granted European Patent No. 4297848 to Envoy Medical Corporation on April 8, 2026. Also titled Combination Implant System with Removable Earplug Sensor and Implanted Battery. This patent relates to using an external device to indicate a signal within a fully implantable cochlear implant system for analysis, receive a representative signal from the cochlear implant system, and output a representation of the signal.
The European Patent Office also granted European Patent No. 4297851 to Envoy Medical Corporation on April 8, 2026. Titled Cochlear Implant System with Integrated Signal Analysis Functionality. This patent relates to using an external device to indicate a signal within a fully implantable cochlear implant system for analysis, receive a representative signal from the cochlear implant system, and output a representation of the signal.
Additionally, the European Patent Office is expected to grant European Patent No. 4297862 to Envoy Medical Corporation on June 10, 2026. Titled Recharge System for Implantable Battery, the patent relates to systems and methods for predicting cumulative thermal dose associated with charging an implanted rechargeable battery and monitoring charging parameters, including temperature, to help minimize charging time while maintaining safe thermal conditions.
To be added to the Envoy Medical email distribution list, please email Envoy@kcsa.com with COCH in the subject line.
About Envoy Medical, Inc.
Envoy Medical (NASDAQ: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.
About the Fully Implanted Acclaim® Cochlear Implant
We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.
The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.
The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.
CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.
About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.
*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.
Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.
Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.